11/12/2021 | Press release | Distributed by Public on 11/12/2021 13:43
Delaware
(State or other jurisdiction
of incorporation or organization)
|
13-3986004
(I.R.S. Employer
Identification No.)
|
Title of each class
|
Trading
Symbol(s) |
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
SSKN
|
The NASDAQ Stock Market LLC
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
|||
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
|||
Emerging growth company ☐
|
Part I. Financial Information:
|
PAGE
|
||
ITEM 1. Financial Statements:
|
|||
a.
|
Condensed Consolidated Balance Sheets as of September 30, 2021 (unaudited) and December 31, 2020
|
1
|
|
b.
|
Condensed Consolidated Statements of Operations for the three months ended September 30, 2021 and, 2020 (unaudited)
|
2
|
|
c.
|
Condensed Consolidated Statements of Operations for the nine months ended September 30, 2021 and, 2020 (unaudited)
|
3
|
|
d.
|
Condensed Consolidated Statement of Changes in Stockholders' Equity for the nine months ended September 30, 2020 (unaudited)
|
4
|
|
e |
Condensed Consolidated Statement of Changes in Stockholders' Equity for the nine months ended September 30, 2021 (unaudited)
|
5 | |
f.
|
Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and, 2020 (unaudited)
|
6
|
|
g.
|
Notes to Unaudited Condensed Consolidated Financial Statements
|
7
|
|
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
|
25
|
||
ITEM 3. Quantitative and Qualitative Disclosure about Market Risk
|
34
|
||
ITEM 4. Controls and Procedures
|
34
|
||
Part II. Other Information:
|
|||
ITEM 1. Legal Proceedings
|
35
|
||
ITEM 1A. Risk Factors
|
35
|
||
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
35
|
||
ITEM 3. Defaults Upon Senior Securities
|
35
|
||
ITEM 4. Mine Safety Disclosures
|
35
|
||
ITEM 5. Other Information
|
35
|
||
ITEM 6. Exhibits
|
36
|
||
Signatures
|
37
|
||
Certifications
|
E-31.1
|
September 30, 2021
|
December 31, 2020
|
|||||||
ASSETS
|
(unaudited)
|
|||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
13,047
|
$
|
10,604
|
||||
Restricted cash
|
-
|
7,508
|
||||||
Accounts receivable, net of allowance for doubtful accounts of $248and $274, respectively
|
3,151
|
2,944
|
||||||
Inventories
|
3,225
|
3,444
|
||||||
Prepaid expenses and other current assets
|
623
|
331
|
||||||
Total current assets
|
20,046
|
24,831
|
||||||
Property and equipment, net
|
6,403
|
5,529
|
||||||
Operating lease right-of-use assets, net
|
727
|
988
|
||||||
Intangible assets, net
|
10,546
|
6,345
|
||||||
Goodwill
|
8,803
|
8,803
|
||||||
Other assets
|
233
|
282
|
||||||
Total assets
|
$
|
46,758
|
$
|
46,778
|
||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Note payable
|
$
|
-
|
$
|
7,275
|
||||
Current portion of long-term debt
|
-
|
1,478
|
||||||
Accounts payable
|
2,480
|
2,764
|
||||||
Other accrued liabilities
|
5,548
|
4,690
|
||||||
Current portion of operating lease liabilities
|
359
|
369
|
||||||
Deferred revenues
|
3,767
|
2,262
|
||||||
Total current liabilities
|
12,154
|
18,838
|
||||||
Long-term liabilities:
|
||||||||
Long-term debt, net
|
7,282
|
1,050
|
||||||
Deferred tax liability
|
266
|
254
|
||||||
Long-term operating lease liabilities, net
|
445
|
710
|
||||||
Other liabilities
|
428
|
34
|
||||||
Total liabilities
|
20,575
|
20,886
|
||||||
Commitments and contingencies (see Note 15)
|
||||||||
Stockholders' equity:
|
||||||||
Series C Convertible Preferred Stock, $0.10par value, 10,000,000shares authorized; 0shares issued and outstanding at September 30, 2021and December 31, 2020
|
-
|
-
|
||||||
Common Stock, $0.001par value, 150,000,000shares authorized; 34,364,679, and 33,801,045shares issued and outstanding at September 30, 2021and December 31, 2020, respectively
|
34
|
34
|
||||||
Additional paid-in capital
|
246,979
|
244,831
|
||||||
Accumulated deficit
|
(220,830
|
)
|
(218,973
|
)
|
||||
Total stockholders' equity
|
26,183
|
25,892
|
||||||
Total liabilities and stockholders' equity
|
$
|
46,758
|
$
|
46,778
|
For the Three Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Revenues, net
|
$
|
7,711
|
$
|
5,613
|
||||
Cost of revenues
|
2,335
|
2,383
|
||||||
Gross profit
|
5,376
|
3,230
|
||||||
Operating expenses:
|
||||||||
Engineering and product development
|
371
|
411
|
||||||
Selling and marketing
|
3,295
|
2,051
|
||||||
General and administrative
|
2,175
|
1,929
|
||||||
5,841
|
4,391
|
|||||||
Loss from operations
|
(465
|
)
|
(1,161
|
)
|
||||
Interest expense net
|
(52
|
)
|
(21
|
)
|
||||
Loss before income taxes
|
(517
|
)
|
(1,182
|
)
|
||||
Income tax expense
|
(4
|
)
|
(72
|
)
|
||||
Net loss
|
$
|
(521
|
)
|
$
|
(1,254
|
)
|
||
Loss per common share - basic and diluted
|
$
|
(0.02
|
)
|
$
|
(0.04
|
)
|
||
Weighted average shares of common stock outstanding - basic and diluted
|
34,150,438
|
33,754,909
|
For the Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Revenues, net
|
$ |
20,920
|
$
|
16,373
|
||||
Cost of revenues
|
7,070
|
6,780
|
||||||
Gross profit
|
13,850
|
9,593
|
||||||
Operating expenses:
|
||||||||
Engineering and product development
|
1,158
|
950
|
||||||
Selling and marketing
|
9,387
|
6,446
|
||||||
General and administrative
|
7,085
|
5,921
|
||||||
17,630
|
13,317
|
|||||||
Loss from operations
|
(3,780
|
)
|
(3,724
|
)
|
||||
Other income (expense), net:
|
||||||||
Gain on forgiveness of debt
|
2,028
|
-
|
||||||
Interest expense, net
|
(93
|
)
|
(38
|
)
|
||||
1,935
|
(38
|
)
|
||||||
Loss before income taxes
|
(1,845
|
)
|
(3,762
|
)
|
||||
Income tax expense
|
(12
|
)
|
(207
|
)
|
||||
Net loss
|
$
|
(1,857
|
)
|
$
|
(3,969
|
)
|
||
Loss attributable to common shares
|
$ |
(1,857 | ) | $ | (3,947 | ) | ||
Loss attributable to Preferred Series C shares
|
$ |
-
|
$
|
(22
|
)
|
|||
Loss per common share - basic and diluted
|
$
|
(0.05
|
)
|
$
|
(0.12
|
)
|
||
Weighted average common shares outstanding - basic and diluted
|
33,944,321
|
33,551,070
|
||||||
Loss per Preferred Series C share - basic and diluted
|
-
|
$
|
(43.73
|
)
|
||||
Shares used in computing loss per basic and diluted Preferred Series C Shares
|
-
|
491
|
Convertible
Preferred Stock - Series C
|
Common Stock
|
Additional Paid-In
|
Accumulated
|
|||||||||||||||||||||||||
Shares
|
Amount
|
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
||||||||||||||||||||||
BALANCE, January 1, 2020
|
2,103
|
$
|
1
|
32,932,273
|
$
|
33
|
$
|
243,180
|
$
|
(214,561
|
)
|
$
|
28,653
|
|||||||||||||||
Stock-based compensation
|
-
|
-
|
-
|
-
|
430
|
-
|
430
|
|||||||||||||||||||||
Conversion of convertible preferred stock into common stock
|
(2,103
|
)
|
(1
|
)
|
782,089
|
1
|
- |
- |
-
|
|||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(1,035
|
)
|
(1,035
|
)
|
|||||||||||||||||||
BALANCE, March 31, 2020
|
-
|
$
|
-
|
33,714,362
|
$
|
34
|
$
|
243,610
|
$
|
(215,596
|
)
|
$
|
28,048
|
|||||||||||||||
Stock-based compensation
|
-
|
-
|
- |
- |
410
|
-
|
410
|
|||||||||||||||||||||
Issuance of restricted stock
|
-
|
-
|
40,547
|
-
|
- |
- |
-
|
|||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(1,680
|
)
|
(1,680
|
)
|
|||||||||||||||||||
BALANCE, June 30, 2020
|
-
|
$
|
-
|
33,754,909
|
$
|
34
|
$
|
244,020
|
$
|
(217,276
|
)
|
$
|
26,778
|
|||||||||||||||
Stock based compensation |
- |
- |
- |
- |
403 |
- |
403 |
|||||||||||||||||||||
Net loss | - | - | - | - | - | (1,254 | ) | (1,254 | ) | |||||||||||||||||||
BALANCE, September 30, 2020
|
- | $ | - | 33,754,909 | $ | 34 | $ | 244,423 | $ | (218,530 | ) | $ | 25,927 |
Common Stock
|
Additional Paid-In
|
Accumulated
|
||||||||||||||||||
Shares
|
Amount
|
Capital
|
Deficit
|
Total
|
||||||||||||||||
BALANCE, January 1, 2021
|
33,801,045
|
$
|
34
|
$
|
244,831
|
$
|
(218,973
|
)
|
$
|
25,892
|
||||||||||
Stock-based compensation
|
-
|
-
|
662
|
-
|
662
|
|||||||||||||||
Issuance of restricted stock
|
16,260
|
-
|
-
|
-
|
-
|
|||||||||||||||
Net loss
|
-
|
-
|
-
|
(2,418
|
)
|
(2,418
|
)
|
|||||||||||||
BALANCE, March 31, 2021
|
33,817,305
|
$
|
34
|
$
|
245,493
|
$
|
(221,391
|
)
|
$
|
24,136
|
||||||||||
Stock-based compensation
|
-
|
-
|
581
|
- |
581
|
|||||||||||||||
Issuance of restricted stock
|
71,934
|
-
|
-
|
- |
-
|
|||||||||||||||
Net income
|
-
|
-
|
-
|
1,082
|
1,082
|
|||||||||||||||
BALANCE, June 30, 2021
|
33,889,239
|
$
|
34
|
$
|
246,074
|
$
|
(220,309
|
)
|
$
|
25,799
|
||||||||||
Stock-based compensation | - | - | 320 | - | 320 | |||||||||||||||
Exercise of stock options
|
329,076 | - | - | - | - | |||||||||||||||
Issuance of restricted stock
|
146,364 | - | - | - | - | |||||||||||||||
Issuance of warrants
|
- | - | 585 | - | 585 | |||||||||||||||
Net Loss | - | (521 | ) | (521 | ) | |||||||||||||||
BALANCE, September 30, 2021
|
34,364,679 | $ | 34 | $ | 246,979 | $ | (220,830 | ) | $ | 26,183 |
For the Nine Months Ended
September 30,
|
||||||||
2021
|
2020
|
|||||||
Cash Flows From Operating Activities:
|
||||||||
Net loss
|
$
|
(1,857
|
)
|
$
|
(3,969
|
)
|
||
Adjustments to reconcile net loss to net cash provided by operating activities:
|
||||||||
Depreciation and amortization
|
2,689
|
2,793
|
||||||
Amortization of right-of-use asset
|
261
|
242
|
||||||
Provision (recoveries) for doubtful accounts
|
(26
|
)
|
65
|
|||||
Stock-based compensation
|
1,563
|
1,243
|
||||||
Loss on disposal of property and equipment
|
73 | 23 | ||||||
Gain on forgiveness of debt
|
(2,028 | ) | - | |||||
Deferred taxes
|
12
|
207
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(181
|
)
|
1,811
|
|||||
Inventories
|
219
|
(475
|
)
|
|||||
Prepaid expenses and other assets
|
(243
|
)
|
98
|
|||||
Accounts payable
|
(284
|
)
|
1,608
|
|||||
Other accrued liabilities
|
859
|
(576
|
)
|
|||||
Other liabilities
|
(88
|
)
|
(126
|
)
|
||||
Operating lease liabilities
|
(275
|
)
|
(226
|
)
|
||||
Deferred revenues
|
145
|
(968
|
)
|
|||||
Net cash provided by operating activities
|
839
|
1,750
|
||||||
Cash Flows From Investing Activities: | ||||||||
Purchase of property and equipment
|
(2,523 | ) | (1,447 | ) | ||||
Cash paid in connection with Ra Medical asset acquisition
|
(3,473 | ) | - | |||||
Net cash used in investing activities
|
(5,996 | ) | (1,447 | ) | ||||
Cash Flows From Financing Activities
|
||||||||
Proceeds from Senior Term Facility borrowings, net of fees
|
7,867
|
-
|
||||||
Repayment of note payable
|
(7,275 | ) | - | |||||
Proceeds from (repayment of) long-term debt
|
(500 | ) | 2,528 | |||||
Net cash provided by financing activities
|
92
|
2,528 |
||||||
Net (decrease) increase in cash and cash equivalents and restricted cash
|
(5,065
|
)
|
2,831
|
|||||
Cash, cash equivalents and restricted cash, beginning of period
|
18,112
|
15,629
|
||||||
Cash, cash equivalents and restricted cash, end of period
|
$
|
13,047
|
$
|
18,460
|
||||
Cash and cash equivalents
|
$
|
13,047
|
$
|
11,063
|
||||
Restricted cash
|
-
|
7,397
|
||||||
$
|
13,047
|
$
|
18,460
|
|||||
Supplemental information of cash and non-cash transactions:
|
||||||||
Cash paid for interest
|
$
|
109
|
$
|
157
|
||||
Fair value of warrants issued in connection with debt
|
$ | 585 | $ | - | ||||
Assumed deferred revenue in connection with Ra Medical asset acquisition | $ | 1,841 | $ | - |
•
|
Level 1 - unadjusted quoted prices are available in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.
|
|
•
|
Level 2 - pricing inputs are other than quoted prices in active markets that are directly observable for the asset or liability or indirectly observable through corroboration with observable market data.
|
|
•
|
Level 3 - pricing inputs are unobservable for the non-financial asset or liability and only used when there is little, if any, market activity for the non-financial asset or liability at the measurement date. The inputs into the determination of fair value require significant management judgment or estimation. Fair value is determined using comparable market transactions and other valuation methodologies, adjusted as appropriate for liquidity, credit, market and/or other risk factors.
|
September 30, |
||||||||
2021 | 2020 | |||||||
Common stock purchase warrants
|
373,626 | 149,901 | ||||||
Restricted stock units
|
144,497 | 119,330 | ||||||
Common stock options
|
3,963,889 | 4,908,038 | ||||||
Total
|
4,482,012 | 5,177,269 |
Three Months Ended
September 30, 2021
|
||||||||||||
Dermatology Recurring Procedures
|
Dermatology Procedures Equipment
|
TOTAL
|
||||||||||
Domestic
|
$
|
5,370
|
$
|
519
|
$
|
5,889
|
||||||
Foreign
|
340
|
1,482
|
1,822
|
|||||||||
Total
|
$
|
5,710
|
$
|
2,001
|
$
|
7,711
|
Nine Months Ended
September 30, 2021
|
||||||||||||
Dermatology Recurring Procedures
|
Dermatology Procedures Equipment
|
TOTAL
|
||||||||||
Domestic
|
$
|
14,923
|
$
|
1,113
|
$
|
16,036
|
||||||
Foreign
|
918
|
3,966
|
4,884
|
|||||||||
Total
|
$
|
15,841
|
$
|
5,079
|
$
|
20,920
|
Three Months Ended
September 30, 2020
|
||||||||||||
Dermatology Recurring Procedures
|
Dermatology Procedures Equipment
|
TOTAL
|
||||||||||
Domestic
|
$
|
3,690
|
$
|
261
|
$
|
3,951
|
||||||
Foreign
|
145
|
1,517
|
1,662
|
|||||||||
Total
|
$
|
3,835
|
$
|
1,778
|
$
|
5,613
|
Nine Months Ended
September 30, 2020
|
||||||||||||
Dermatology Recurring Procedures
|
Dermatology Procedures Equipment
|
TOTAL
|
||||||||||
Domestic
|
$
|
11,957
|
$
|
701
|
$
|
12,658
|
||||||
Foreign
|
375
|
3,340
|
3,715
|
|||||||||
Total
|
$
|
12,332
|
$
|
4,041
|
$
|
16,373
|
Remaining 2021
|
$
|
390
|
||
2022
|
1,556
|
|||
2023
|
1,479
|
|||
2024
|
1,076
|
|||
2025
|
362
|
|||
Thereafter
|
-
|
|||
Total
|
$
|
4,863
|
Consideration:
|
||||
Cash payment
|
$
|
3,700
|
||
Transaction costs
|
57
|
|||
Total consideration
|
$
|
3,757
|
||
Assets acquired:
|
||||
Inventory
|
$
|
284
|
||
Customer lists
|
5,314
|
|||
Total assets acquired
|
$
|
5,598
|
||
Liabilities assumed:
|
||||
Deferred revenues - service contracts
|
$
|
1,841
|
||
Total liabilities assumed
|
$
|
1,841
|
||
Net assets acquired
|
$
|
3,757
|
September 30, 2021
|
December 31, 2020
|
|||||||
Raw materials and work-in-process
|
$
|
3,024
|
$
|
2,949
|
||||
Finished goods
|
201
|
495
|
||||||
Total inventories
|
$
|
3,225
|
$
|
3,444
|
September 30, 2021
|
December 31, 2020
|
|||||||
Lasers placed-in-service
|
$
|
25,190
|
$
|
22,942
|
||||
Equipment, computer hardware and software
|
224
|
146
|
||||||
Furniture and fixtures
|
236
|
243
|
||||||
Leasehold improvements
|
43
|
43
|
||||||
25,693
|
23,374
|
|||||||
Accumulated depreciation and amortization
|
(19,290
|
)
|
(17,845
|
)
|
||||
Property and equipment, net
|
$
|
6,403
|
$
|
5,529
|
Balance
|
Accumulated
Amortization
|
Intangible
assets, net
|
||||||||||
Core technology
|
$
|
5,700
|
$
|
(3,562
|
)
|
$
|
2,138
|
|||||
Product technology
|
2,000
|
(2,000
|
)
|
-
|
||||||||
Customer relationships
|
6,900
|
(4,313
|
)
|
2,587
|
||||||||
Tradenames
|
1,500
|
(938
|
)
|
562
|
||||||||
Pharos customer list |
5,314 |
(55 | ) |
5,259 |
||||||||
$
|
21,414
|
$
|
(10,868
|
)
|
$
|
10,546
|
Balance
|
Accumulated
Amortization
|
Intangible
assets, net
|
||||||||||
Core technology
|
$
|
5,700
|
$
|
(3,135
|
)
|
$
|
2,565
|
|||||
Product technology
|
2,000
|
(2,000
|
)
|
-
|
||||||||
Customer relationships
|
6,900
|
(3,795
|
)
|
3,105
|
||||||||
Tradenames
|
1,500
|
(825
|
)
|
675
|
||||||||
$
|
16,100
|
$
|
(9,755
|
)
|
$
|
6,345
|
Remaining 2021
|
$
|
463
|
||
2022
|
1,853
|
|||
2023
|
1,853
|
|||
2024
|
1,853
|
|||
2025
|
1,148
|
|||
Thereafter |
3,376 | |||
Total
|
$
|
10,546
|
September 30, 2021
|
December 31, 2020
|
|||||||
Accrued warranty, current
|
$
|
54
|
$
|
87
|
||||
Accrued compensation, including commissions and vacation
|
1,578
|
891
|
||||||
Accrued state sales, use and other taxes
|
3,152
|
3,105
|
||||||
Accrued professional fees and other accrued liabilities
|
764
|
607
|
||||||
Total other accrued liabilities
|
$
|
5,548
|
$
|
4,690
|
Three Months Ended,
September 30,
|
Nine Months Ended,
September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Accrual at beginning of period
|
$
|
98
|
$
|
139
|
$
|
113
|
$
|
232
|
||||||||
Additions charged to warranty expense
|
11
|
37
|
52
|
46
|
||||||||||||
Expiring warranties/claimed satisfied
|
(28
|
)
|
(41
|
)
|
(84
|
)
|
(143
|
)
|
||||||||
Total
|
81
|
135
|
81
|
135
|
||||||||||||
Less: current portion
|
(54
|
)
|
(107
|
)
|
(54
|
)
|
(107
|
)
|
||||||||
Total long-term accrued warranty costs
|
$
|
27
|
$
|
28
|
$
|
27
|
$
|
28
|
2024
|
$
|
1,000
|
||
2025
|
4,000
|
|||
2026
|
3,000
|
|||
Total
|
$
|
8,000
|
Number of
shares
|
Weighted
average
exercise
price
per share
|
Weighted
average
remaining
contractual
term (years)
|
||||||||||
Outstanding at January 1, 2021
|
5,292,888
|
$
|
1.87
|
|||||||||
Granted
|
2,043,714
|
$
|
1.67
|
|||||||||
Exercised
|
(1,557,628
|
)
|
$
|
1.12
|
||||||||
Forfeited/expired
|
(1,815,085
|
)
|
$
|
1.84
|
||||||||
Outstanding at September 30, 2021 | 3,963,889 | $ | 2.05 | 8.2 | ||||||||
Exercisable at September 30, 2021 | 1,236,841 | $ | 2.77 | 5.6 |
Expected volatility
|
90.4
|
%
|
||
Risk‑free interest rate
|
1.0
|
%
|
||
Expected life (in years)
|
5.9
|
|||
Expected dividend yield
|
0
|
%
|
||
Fair value of common stock
|
$
|
1.68
|
Number of
shares
|
Weighted
average
grant
date
fair value
|
|||||||
Unvested at January 1, 2021
|
-
|
$
|
-
|
|||||
Granted
|
290,861
|
$
|
1.44
|
|||||
Vested
|
(146,364
|
)
|
$
|
1.42
|
||||
Unvested at September 30, 2021 | 144,497 | $ | 1.45 |
Dermatology
Recurring
Procedures
|
Dermatology
Procedures
Equipment
|
TOTAL
|
||||||||||
Revenues
|
$
|
5,710
|
$
|
2,001
|
$
|
7,711
|
||||||
Costs of revenues
|
1,512
|
823
|
2,335
|
|||||||||
Gross profit
|
4,198
|
1,178
|
5,376
|
|||||||||
Gross profit %
|
73.5
|
%
|
58.9
|
%
|
69.7
|
%
|
||||||
Allocated operating expenses:
|
||||||||||||
Engineering and product development
|
333
|
38
|
371
|
|||||||||
Selling and marketing
|
3,094
|
201
|
3,295
|
|||||||||
Unallocated operating expenses
|
-
|
-
|
2,175
|
|||||||||
3,427
|
239
|
5,841
|
||||||||||
Income (loss) from operations
|
771
|
939
|
(465
|
)
|
||||||||
Interest expense, net
|
-
|
-
|
(52
|
)
|
||||||||
Income (loss) before income taxes
|
$
|
771
|
$
|
939
|
$
|
(517
|
)
|
Dermatology
Recurring
Procedures |
Dermatology
Procedures
Equipment
|
TOTAL
|
||||||||||
Revenues
|
$
|
15,841
|
$
|
5,079
|
$
|
20,920
|
||||||
Costs of revenues
|
4,648
|
2,422
|
7,070
|
|||||||||
Gross profit
|
11,193
|
2,657
|
13,850
|
|||||||||
Gross profit %
|
70.7 |
% |
52.3 |
% |
66.2 |
% |
||||||
Allocated operating expenses:
|
||||||||||||
Engineering and product development
|
1,013
|
145
|
1,158
|
|||||||||
Selling and marketing
|
8,805
|
582
|
9,387
|
|||||||||
Unallocated operating expenses
|
-
|
-
|
7,085
|
|||||||||
9,818
|
727
|
17,630
|
||||||||||
Income (loss) from operations
|
1,375
|
1,930
|
(3,780
|
)
|
||||||||
Gain on forgiveness of debt
|
- | - | 2,028 | |||||||||
Interest expense, net
|
-
|
-
|
(93
|
)
|
||||||||
Income (loss) before income taxes
|
$
|
1,375
|
$
|
1,930
|
$
|
(1,845
|
)
|
Dermatology
Recurring
Procedures
|
Dermatology
Procedures
Equipment
|
TOTAL
|
||||||||||
Revenues
|
$
|
3,835
|
$
|
1,778
|
$
|
5,613
|
||||||
Costs of revenues
|
1,368
|
1,015
|
2,383
|
|||||||||
Gross profit
|
2,467
|
763
|
3,230
|
|||||||||
Gross profit %
|
64.3
|
%
|
42.9
|
%
|
57.5
|
%
|
||||||
Allocated operating expenses:
|
||||||||||||
Engineering and product development
|
329
|
82
|
411
|
|||||||||
Selling and marketing
|
1,883
|
168
|
2,051
|
|||||||||
Unallocated operating expenses
|
-
|
-
|
1,929
|
|||||||||
2,212
|
250
|
4,391
|
||||||||||
Income (loss) from operations
|
255
|
513
|
(1,161
|
)
|
||||||||
Interest expense, net
|
-
|
-
|
(21
|
)
|
||||||||
Income (loss) before income taxes
|
$
|
255
|
$
|
513
|
$
|
(1,182
|
)
|
Dermatology
Recurring
Procedures
|
Dermatology
Procedures
Equipment
|
TOTAL
|
||||||||||
Revenues
|
$
|
12,332
|
$
|
4,041
|
$
|
16,373
|
||||||
Costs of revenues
|
4,534
|
2,246
|
6,780
|
|||||||||
Gross profit
|
7,798
|
1,795
|
9,593
|
|||||||||
Gross profit %
|
63.2
|
%
|
44.4
|
%
|
58.6
|
%
|
||||||
Allocated operating expenses:
|
||||||||||||
Engineering and product development
|
828
|
122
|
950
|
|||||||||
Selling and marketing
|
6,021
|
425
|
6,446
|
|||||||||
Unallocated operating expenses
|
-
|
-
|
5,921
|
|||||||||
|
6,849
|
547
|
13,317
|
|||||||||
Income (loss) from operations
|
949
|
1,248
|
(3,724
|
)
|
||||||||
Interest expense, net
|
-
|
-
|
(38
|
)
|
||||||||
Income (loss) before income taxes
|
$
|
949
|
$
|
1,248
|
$
|
(3,762
|
)
|
For the year ending December 31,
|
Amount
|
|||
Remaining 2021
|
$
|
122
|
||
2022
|
371
|
|||
2023
|
242
|
|||
2024
|
186
|
|||
Total remaining lease payments
|
921
|
|||
Less: imputed interest
|
(117
|
)
|
||
Total lease liabilities
|
$
|
804
|
ITEM 2. |
Management's Discussion and Analysis of Financial Condition and Results of Operations.
|
|
• |
XTRAC® Excimer Laser.XTRAC received FDA clearance in 2000 and has since become a widely recognized treatment among dermatologists for psoriasis and other skin diseases. The XTRAC System delivers ultra-narrowband ultraviolet B ("UVB") light to affected areas of skin. Following a series of treatments typically performed twice weekly, psoriasis remission can be achieved, and vitiligo patches can be re-pigmented. XTRAC is endorsed by the National Psoriasis Foundation, and its use for psoriasis is covered by nearly all major insurance companies, including Medicare. We estimate that more than half of all major insurance companies now offer reimbursement for vitiligo as well, a figure that is increasing.
|
|
• |
In the third quarter of 2018, we announced the FDA granted clearance for our Multi Micro Dose (MMD) tip for our XTRAC excimer laser. The MMD Tip accessory is indicated for use in conjunction with the XTRAC laser system to filter the Narrow Band UVB ("NB-UVB") light at delivery in order to calculate and individualize the maximum non-blistering dose for a particular patient.
|
|
• |
In January 2020, we announced the FDA granted clearance of our XTRAC Momentum Excimer Laser Platform.
|
|
• |
VTRAC® Lamp.VTRAC received FDA clearance in 2005 and provides targeted therapeutic efficacy demonstrated by excimer technology with the simplicity of design and reliability of a lamp system.
|
For the Three Months Ended
September 30,
|
For the Nine Months Ended
September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Dermatology Recurring Procedures
|
$
|
5,710
|
$
|
3,835
|
$
|
15,841
|
$
|
12,332
|
||||||||
Dermatology Procedures Equipment
|
2,001
|
1,778
|
5,079
|
4,041
|
||||||||||||
Total Revenues
|
$
|
7,711
|
$
|
5,613
|
$
|
20,920
|
$
|
16,373
|
For the Three Months Ended
September 30,
|
For the Nine Months Ended
September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Dermatology Recurring Procedures
|
$
|
1,512
|
$
|
1,368
|
$
|
4,648
|
$
|
4,534
|
||||||||
Dermatology Procedures Equipment
|
823
|
1,015
|
2,422
|
2,246
|
||||||||||||
Total Cost of Revenues
|
$
|
2,335
|
$
|
2,383
|
$
|
7,070
|
$
|
6,780
|
Company Profit Analysis
|
For the Three Months Ended
September 30,
|
For the Nine Months Ended
September 30,
|
||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Revenues
|
$
|
7,711
|
$
|
5,613
|
$
|
20,920
|
$
|
16,373
|
||||||||
Cost of revenues
|
2,335
|
2,383
|
7,070
|
6,780
|
||||||||||||
Gross profit
|
$
|
5,376
|
$
|
3,230
|
$
|
13,850
|
$
|
9,593
|
||||||||
Gross profit percentage
|
69.7
|
%
|
57.5
|
%
|
66.2
|
%
|
58.6
|
%
|
Dermatology Recurring Procedures
|
For the Three Months Ended
September 30,
|
For the Nine Months Ended
September 30,
|
||||||||||||||
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|||||||
Revenues
|
$
|
5,710
|
$
|
3,835
|
$
|
15,841
|
$
|
12,332
|
||||||||
Cost of revenues
|
1,512
|
1,368
|
4,648
|
4,534
|
||||||||||||
Gross profit
|
$
|
4,198
|
$
|
2,467
|
$
|
11,193
|
$
|
7,798
|
||||||||
Gross profit percentage
|
73.5
|
%
|
64.3
|
%
|
70.7
|
%
|
63.2
|
%
|
Dermatology Procedures Equipment
|
For the Three Months Ended
September 30,
|
For the Nine Months Ended
September 30,
|
||||||||||||||
2021
|
|
|
2020
|
|
|
2021
|
|
|
2020
|
|||||||
Revenues
|
$
|
2,001
|
$
|
1,778
|
$
|
5,079
|
$
|
4,041
|
||||||||
Cost of revenues
|
823
|
1,015
|
2,422
|
2,246
|
||||||||||||
Gross profit
|
$
|
1,178
|
$
|
763
|
$
|
2,657
|
$
|
1,795
|
||||||||
Gross profit percentage
|
58.9
|
%
|
42.9
|
%
|
52.3
|
%
|
44.4
|
%
|
For the Three Months Ended September 30,
|
For the Nine Months Ended September 30,
|
|||||||||||||||
2021
|
2020
|
2021
|
2020
|
|||||||||||||
Net loss
|
$
|
(521
|
)
|
$
|
(1,254
|
)
|
$
|
(1,857
|
)
|
$
|
(3,969
|
)
|
||||
Adjustments:
|
||||||||||||||||
Depreciation and amortization
|
983
|
807
|
2,689
|
2,793
|
||||||||||||
Amortization of right-of-use-asset
|
87
|
83
|
261
|
242
|
||||||||||||
Loss (gain) on disposal of property and equipment
|
10
|
4
|
73
|
23
|
||||||||||||
Income taxes
|
4
|
72
|
12
|
207
|
||||||||||||
Gain on forgiveness of debt
|
-
|
-
|
(2,028
|
)
|
-
|
|||||||||||
Interest expense, net
|
52
|
21
|
93
|
38
|
||||||||||||
Non-GAAP EBITDA
|
615
|
(267
|
)
|
(757
|
)
|
(666
|
)
|
|||||||||
Stock compensation
|
320
|
403
|
1,563
|
1,243
|
||||||||||||
Non-GAAP adjusted EBITDA
|
$
|
935
|
$
|
136
|
$
|
806
|
$
|
577
|
ITEM 3. |
Quantitative and Qualitative Disclosure about Market Risk
|
ITEM 4. |
Controls and Procedures
|
ITEM 1. |
Legal Proceedings
|
ITEM 1A. |
Risk Factors
|
ITEM 2. |
Unregistered Sales of Equity Securities and Use of Proceeds
|
ITEM 3. |
Defaults Upon Senior Securities.
|
ITEM 4. |
Mine Safety Disclosures
|
ITEM 5. |
Other Information
|
ITEM 6. |
Exhibits
|
3.1
|
||
3.2
|
||
10.1
|
||
10.2
|
||
10.3
|
||
10.4
|
Warrant Agreement to Purchase Shares of the Common Stock of STRATA Skin Sciences, Inc., dated as of September 30, 2021, between STRATA Skin Sciences, Inc. and MidCap Funding XXVII Trust(Incorporated by reference to Exhibit 10.3 contained in our Current Report on Form 8-K as filed on October 4, 2021).
|
|
10.5
|
||
10.6
|
Form of Management Change in Control Agreement
|
|
31.1
|
Rule 13a-14(a) Certificate of Chief Executive Officer
|
|
31.2
|
Rule 13a-14(a) Certificate of Chief Financial Officer
|
|
32.1*
|
Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
XBRL Instance Document
|
|
101.SCH
|
XBRL Taxonomy Schema
|
|
101.CAL
|
XBRL Taxonomy Calculation Linkbase
|
|
101.DEF
|
XBRL Taxonomy Definition Linkbase
|
|
101.LAB
|
XBRL Taxonomy Label Linkbase
|
|
101.PRE
|
XBRL Taxonomy Presentation Linkbase
|
*
|
The certifications attached as Exhibit 32.1 accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed "filed" by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
|
STRATA SKIN SCIENCES, INC.
|
Date November 12, 2021
|
By:
|
/s/ Robert J. Moccia
|
|
Name Robert J. Moccia
|
|||
Title President & Chief Executive Officer
|
Date November 12, 2021
|
By:
|
/s/ Christopher Lesovitz
|
|
Name Christopher Lesovitz
|
|||
Title Chief Financial Officer
|